Avidity Biosciences

Avidity Biosciences is a privately-held biotech company pioneering a new class of precision medicines – Antibody-SIRNA Conjugates (ASC™) – that combines the strengths of monoclonal antibodies and SiRNA-based therapeutics to overcome barriers to the delivery of SIRNA and target genetic drivers of disease. The exit of Riyadh Valley Company comes as a result of the initial public offering of Avidity shares on the NASDAQ market under the symbol: RNA